近两年高层针对创新药板块出台了加快评审、优化定价、商保支付等利好政策，但真正引爆市场的导火索是康方、三生等公司的重磅BD。大量且重磅BD的出现改善了机构对创新药板块利润、现金流的预期。若单以对外BD的抗体分子数量计，国内创新药BD的“无冕之王”当属百奥赛图。01 百奥赛图营业收入大增51.5%，净利润、经营现金流双回正（百奥赛图财报）上半年，百奥赛图实现营收6.21亿，同比增长51.5%。...
Source Link近两年高层针对创新药板块出台了加快评审、优化定价、商保支付等利好政策，但真正引爆市场的导火索是康方、三生等公司的重磅BD。大量且重磅BD的出现改善了机构对创新药板块利润、现金流的预期。若单以对外BD的抗体分子数量计，国内创新药BD的“无冕之王”当属百奥赛图。01 百奥赛图营业收入大增51.5%，净利润、经营现金流双回正（百奥赛图财报）上半年，百奥赛图实现营收6.21亿，同比增长51.5%。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.